Sunday - August 2, 2026
Enhertu Granted Breakthrough Therapy Designation in the US as Post-Neoadjuvant Therapy for Patients With HER2-Positive Early Breast Cancer
December 23, 2025
WILMINGTON, Delaware, Dec. 23 (TNSjou) -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer

Tenth Breakthrough Therapy Designation for AstraZeneca and Daiichi Sankyo's

ENHERTU with the latest based on DESTINY-Breast05 Phase III trial . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products